John Varner - Genprex Chairman, CoFounder
| GNPX Stock | USD 1.00 0.10 9.09% |
Insider
John Varner is Chairman, CoFounder of Genprex
| Age | 67 |
| Address | 3300 Bee Cave Road, Austin, TX, United States, 78746 |
| Phone | 877-774-4679 |
| Web | https://www.genprex.com |
John Varner Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Varner against Genprex stock is an integral part of due diligence when investing in Genprex. John Varner insider activity provides valuable insight into whether Genprex is net buyers or sellers over its current business cycle. Note, Genprex insiders must abide by specific rules, including filing SEC forms every time they buy or sell Genprex'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Varner over six months ago Payment of 2642 shares by John Varner of Genprex subject to Rule 16b-3 | ||
John Varner over a year ago Genprex exotic insider transaction detected |
Genprex Management Efficiency
The company has return on total asset (ROA) of (1.4594) % which means that it has lost $1.4594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1888) %, meaning that it created substantial loss on money invested by shareholders. Genprex's management efficiency ratios could be used to measure how well Genprex manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.27 in 2024. Return On Capital Employed is likely to drop to -4.4 in 2024. At this time, Genprex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 49.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| David Dornan | Elevation Oncology | 46 | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Christine CPA | Mereo BioPharma Group | 43 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| CPA MBA | Kodiak Sciences | 60 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Valerie MD | Elevation Oncology | 46 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Eric Rothe | Greenwich Lifesciences | 49 | |
Management Performance
| Return On Equity | -3.19 | ||||
| Return On Asset | -1.46 |
Genprex Leadership Team
Elected by the shareholders, the Genprex's board of directors comprises two types of representatives: Genprex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genprex. The board's role is to monitor Genprex's management team and ensure that shareholders' interests are well served. Genprex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genprex's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ryan MS, CEO, President | ||
| CMA CPA, Co Controller | ||
| Kalyn Dabbs, Sr Marketing | ||
| Suzanne ThorntonJones, Senior Quality | ||
| David Schloss, Senior Resources | ||
| William Gannon, Member Affairs | ||
| Mark MD, Chief Officer | ||
| MD FACS, Chairman Board | ||
| Catherine Esq, General VP | ||
| Thomas Esq, Senior Licensing | ||
| CPM EMBA, Chief Officer | ||
| John Varner, Chairman, CoFounder |
Genprex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genprex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.19 | ||||
| Return On Asset | -1.46 | ||||
| Current Valuation | 7.87 M | ||||
| Shares Outstanding | 8.51 M | ||||
| Shares Owned By Insiders | 6.40 % | ||||
| Shares Owned By Institutions | 10.90 % | ||||
| Number Of Shares Shorted | 363.38 K | ||||
| Price To Earning | (1.09) X | ||||
| Price To Book | 5.62 X | ||||
| EBITDA | (31.06 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genprex Stock Analysis
When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.